Market Overview:
The global adenovirus vaccine market is expected to grow at a CAGR of 10.8% from 2018 to 2030. The growth in the market can be attributed to the increasing incidence of adenovirus infections, rising demand for vaccines against adenoviruses, and technological advancements in the field of vaccine development. Based on type, the global adenovirus vaccine market is segmented into type 4 vaccines and type 7 vaccines. The type 4 vaccines segment is expected to account for a larger share of the market than the type 7 vaccines segment during the forecast period. This can be attributed to factors such as increased awareness about these viruses among healthcare professionals and patients, growing demand for preventive measures against these viruses, and rising incidence of infections caused by these viruses. Based on application, the global adenovirus vaccine market is divided into research & academic laboratories, pharmaceutical & biotechnology companies, and others (including hospitals & clinics). The research & academic laboratories segment is projected to account for a larger share of this market during 2018-2030 owing to an increase in funding by government organizations for R&D activities pertaining to new generation viral diseases including Adenoviruses .
Product Definition:
The Adenovirus Vaccine is a vaccine that helps protect against the Adenovirus. The importance of the Adenovirus Vaccine is that it can help prevent serious infections caused by the virus.
Type 4 Vaccine:
The Type 4 or sometimes called as the fourth generation vaccine is a recombinant DNA vaccine developed by Merck & Co. It was approved for human use in 1995 and is under clinical investigation. The research on this vaccine began in 1983, which was a collaborative venture between the University of Wisconsin-Madison, New York Medical College and Merck & Co., Inc.
Type 7 Vaccine:
The Type 7 or SARS-CoV-2 is a novel coronavirus, first identified in China in December 2015. The virus has an average fatality rate of 50% among humans and is generally found in the lower respiratory tract of patients. It can also cause pneumonia and breathing problems among non-respiratory organs such as kidney, liver, & heart.
Application Insights:
The application segment includes research & academic laboratories, pharmaceutical and biotechnology companies, and others. The other applications include the manufacturing of vaccines as well as drugs. In 2017, the vaccine manufacturing accounted for a major share in the market due to extensive production of different types of vaccines for several diseases such as measles, chickenpox, influenza etc. by various manufacturers across the world including Merck Sharp & Dohme Ltd., Novartis Vaccines Ltd., Pfizer Global Research Pvt. Ltd., sanofi pasteur LLC among others.
Adenovirus is widely used in genetic engineering procedures for producing therapeutic proteins which can be used to treat a variety of life-threatening conditions such as cystic fibrosis (CF), hemophilia (HV).
Regional Analysis:
North America dominated the global adenovirus vaccine market in 2017. The presence of a strong research base, high healthcare expenditure and awareness levels pertaining to the availability of vaccines are some factors attributing for its large share. Moreover, increasing cases of COVID-19 infections are expected to boost demand for adenovirus based vaccines in this region.
The U.S., which is at the forefront of growth in North America, has witnessed an outbreak due to co-infection with both seasonal and pandemic (H1N1) influenza virus during 2017’s winter season resulting into a significant increase in pediatric population suffering from upper respiratory tract infections along with other associated disorders such as otitis media and bronchitis.
Growth Factors:
- Increasing incidence of Adenovirus infections: The incidence of Adenovirus infections is increasing globally due to the changing lifestyle and environmental conditions. This is expected to drive the demand for Adenovirus vaccines in the coming years.
- Growing awareness about Adenovirus vaccines: There is a growing awareness among people about the benefits of vaccination against Adenoviruses. This is likely to boost the demand for these vaccines in the near future.
- Rising investments in R&D activities: Pharmaceutical companies are investing heavily in R&D activities to develop new and improved vaccine formulations against various types of viruses, including adenoviruses. This is likely to create new opportunities for growth of the global adenovirus vaccine market in future years.
Scope Of The Report
Report Attributes
Report Details
Report Title
Adenovirus Vaccine Market Research Report
By Type
Type 4 Vaccine, Type 7 Vaccine
By Application
Research & Academic Laboratories, Pharmaceutical & Biotechnology Companies, Others
By Companies
Teva Pharmaceuticals, Barr Labs
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
142
Number of Tables & Figures
100
Customization Available
Yes, the report can be customized as per your need.
Global Adenovirus Vaccine Market Report Segments:
The global Adenovirus Vaccine market is segmented on the basis of:
Types
Type 4 Vaccine, Type 7 Vaccine
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Research & Academic Laboratories, Pharmaceutical & Biotechnology Companies, Others
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Teva Pharmaceuticals
- Barr Labs
Highlights of The Adenovirus Vaccine Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Type 4 Vaccine
- Type 7 Vaccine
- By Application:
- Research & Academic Laboratories
- Pharmaceutical & Biotechnology Companies
- Others
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Adenovirus Vaccine Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Adenovirus vaccine is a vaccine that helps protect people from Adenovirus. Adenovirus can cause serious respiratory illness, including pneumonia, bronchitis, and even death in young children and adults. The vaccine helps prevent these illnesses by helping to protect the body's immune system against the virus.
Some of the major players in the adenovirus vaccine market are Teva Pharmaceuticals, Barr Labs.
The adenovirus vaccine market is expected to grow at a compound annual growth rate of 10.8%.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Adenovirus Vaccine Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Adenovirus Vaccine Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Adenovirus Vaccine Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Adenovirus Vaccine Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Adenovirus Vaccine Market Size & Forecast, 2018-2028
4.5.1 Adenovirus Vaccine Market Size and Y-o-Y Growth
4.5.2 Adenovirus Vaccine Market Absolute $ Opportunity
Chapter 5 Global Adenovirus Vaccine Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Adenovirus Vaccine Market Size Forecast by Type
5.2.1 Type 4 Vaccine
5.2.2 Type 7 Vaccine
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Adenovirus Vaccine Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Adenovirus Vaccine Market Size Forecast by Applications
6.2.1 Research & Academic Laboratories
6.2.2 Pharmaceutical & Biotechnology Companies
6.2.3 Others
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Adenovirus Vaccine Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Adenovirus Vaccine Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Adenovirus Vaccine Analysis and Forecast
9.1 Introduction
9.2 North America Adenovirus Vaccine Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Adenovirus Vaccine Market Size Forecast by Type
9.6.1 Type 4 Vaccine
9.6.2 Type 7 Vaccine
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Adenovirus Vaccine Market Size Forecast by Applications
9.10.1 Research & Academic Laboratories
9.10.2 Pharmaceutical & Biotechnology Companies
9.10.3 Others
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Adenovirus Vaccine Analysis and Forecast
10.1 Introduction
10.2 Europe Adenovirus Vaccine Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Adenovirus Vaccine Market Size Forecast by Type
10.6.1 Type 4 Vaccine
10.6.2 Type 7 Vaccine
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Adenovirus Vaccine Market Size Forecast by Applications
10.10.1 Research & Academic Laboratories
10.10.2 Pharmaceutical & Biotechnology Companies
10.10.3 Others
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Adenovirus Vaccine Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Adenovirus Vaccine Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Adenovirus Vaccine Market Size Forecast by Type
11.6.1 Type 4 Vaccine
11.6.2 Type 7 Vaccine
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Adenovirus Vaccine Market Size Forecast by Applications
11.10.1 Research & Academic Laboratories
11.10.2 Pharmaceutical & Biotechnology Companies
11.10.3 Others
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Adenovirus Vaccine Analysis and Forecast
12.1 Introduction
12.2 Latin America Adenovirus Vaccine Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Adenovirus Vaccine Market Size Forecast by Type
12.6.1 Type 4 Vaccine
12.6.2 Type 7 Vaccine
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Adenovirus Vaccine Market Size Forecast by Applications
12.10.1 Research & Academic Laboratories
12.10.2 Pharmaceutical & Biotechnology Companies
12.10.3 Others
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Adenovirus Vaccine Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Adenovirus Vaccine Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Adenovirus Vaccine Market Size Forecast by Type
13.6.1 Type 4 Vaccine
13.6.2 Type 7 Vaccine
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Adenovirus Vaccine Market Size Forecast by Applications
13.10.1 Research & Academic Laboratories
13.10.2 Pharmaceutical & Biotechnology Companies
13.10.3 Others
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Adenovirus Vaccine Market: Competitive Dashboard
14.2 Global Adenovirus Vaccine Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Teva Pharmaceuticals
14.3.2 Barr Labs
